CL2020002967A1 - Formas cristalinas de un inhibidor de tlr7/tlr8 - Google Patents
Formas cristalinas de un inhibidor de tlr7/tlr8Info
- Publication number
- CL2020002967A1 CL2020002967A1 CL2020002967A CL2020002967A CL2020002967A1 CL 2020002967 A1 CL2020002967 A1 CL 2020002967A1 CL 2020002967 A CL2020002967 A CL 2020002967A CL 2020002967 A CL2020002967 A CL 2020002967A CL 2020002967 A1 CL2020002967 A1 CL 2020002967A1
- Authority
- CL
- Chile
- Prior art keywords
- crystalline forms
- pyrazolo
- pyridin
- methyl
- tlr7
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- OXDQXRVWDYGAHX-SAVAPUMLSA-N (3S)-N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]morpholine-3-carboxamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(=O)[C@H]1NCCOC1)C OXDQXRVWDYGAHX-SAVAPUMLSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 abstract 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 abstract 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 abstract 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 abstract 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000001981 dermatomyositis Diseases 0.000 abstract 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
- 208000002557 hidradenitis Diseases 0.000 abstract 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000005987 polymyositis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018087448 | 2018-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002967A1 true CL2020002967A1 (es) | 2021-04-30 |
Family
ID=67145832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002967A CL2020002967A1 (es) | 2018-05-18 | 2020-11-16 | Formas cristalinas de un inhibidor de tlr7/tlr8 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12084460B2 (enExample) |
| EP (1) | EP3793998A1 (enExample) |
| JP (2) | JP7407740B2 (enExample) |
| KR (1) | KR20210013554A (enExample) |
| CN (1) | CN112119078A (enExample) |
| AR (1) | AR117573A1 (enExample) |
| AU (1) | AU2019268583B2 (enExample) |
| BR (1) | BR112020022738A2 (enExample) |
| CA (1) | CA3097312A1 (enExample) |
| CL (1) | CL2020002967A1 (enExample) |
| MX (2) | MX2020012259A (enExample) |
| TW (2) | TW202417000A (enExample) |
| WO (1) | WO2019220390A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019155042A1 (en) | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| US12157746B2 (en) | 2018-06-05 | 2024-12-03 | Hoffmann-La Roche Inc. | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease |
| EP3807270B1 (en) | 2018-06-12 | 2023-09-13 | F. Hoffmann-La Roche AG | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| US11952363B2 (en) | 2018-07-23 | 2024-04-09 | Hoffmann-La Roche Inc. | Piperazine compounds for the treatment of autoimmune disease |
| CN112638908A (zh) | 2018-09-04 | 2021-04-09 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的苯并噻唑类化合物 |
| WO2020048596A1 (en) | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel pyrazolopyridine compounds for the treatment of autoimmune disease |
| EP3847170B1 (en) | 2018-09-06 | 2022-06-22 | F. Hoffmann-La Roche AG | Novel cyclic amidine compounds for the treatment of autoimmune disease |
| CN114599652B (zh) | 2019-10-31 | 2024-07-12 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物 |
| EP4061816A1 (en) | 2019-11-19 | 2022-09-28 | F. Hoffmann-La Roche AG | Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| EP4061821B1 (en) | 2019-11-20 | 2025-08-06 | F. Hoffmann-La Roche AG | Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease |
| JP2023533807A (ja) | 2020-07-14 | 2023-08-04 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物 |
| US11661431B2 (en) | 2021-04-16 | 2023-05-30 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| TW202440078A (zh) | 2021-09-10 | 2024-10-16 | 美商基利科學股份有限公司 | 噻吩并吡咯化合物 |
| PE20250401A1 (es) * | 2021-09-24 | 2025-02-11 | Hoffmann La Roche | Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades auto/inmunitarias |
| AU2023207313A1 (en) * | 2022-01-11 | 2024-06-13 | Novartis Ag | Tlr7/8-antagonist for treating sjögren's syndrome or mixed connective tissue disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11507052A (ja) | 1995-06-07 | 1999-06-22 | スージェン・インコーポレーテッド | キナゾリンおよび医薬組成物 |
| EP1940819A1 (en) | 2005-08-16 | 2008-07-09 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
| EP3238722B1 (en) | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones |
| EA039373B1 (ru) | 2012-02-08 | 2022-01-19 | Янссен Сайенсиз Айрлэнд Юси | Производные пиперидино-пиримидина для лечения вирусных инфекций |
| EA029281B1 (ru) | 2013-07-30 | 2018-03-30 | Джилид Коннектикут, Инк. | Полиморф ингибиторов syk |
| AU2016312011B2 (en) * | 2015-08-25 | 2021-02-04 | Beigene, Ltd. | Process for preparing Parp inhibitor, crystalline forms, and uses thereof |
| BR112018074911B1 (pt) * | 2016-06-30 | 2023-01-17 | Kimberly-Clark Worldwide, Inc. | Processo para fabricar um compósito de espuma e fibra, compósito de espuma e fibra, e, artigo absorvente |
| EP4059934B1 (en) * | 2016-09-09 | 2026-07-29 | Novartis AG | Compounds and compositions as inhibitors of endosomal toll-like receptors |
-
2019
- 2019-05-16 WO PCT/IB2019/054066 patent/WO2019220390A1/en not_active Ceased
- 2019-05-16 KR KR1020207032942A patent/KR20210013554A/ko not_active Ceased
- 2019-05-16 BR BR112020022738-2A patent/BR112020022738A2/pt not_active IP Right Cessation
- 2019-05-16 CN CN201980032642.0A patent/CN112119078A/zh active Pending
- 2019-05-16 EP EP19735624.9A patent/EP3793998A1/en not_active Withdrawn
- 2019-05-16 AR ARP190101308A patent/AR117573A1/es not_active Application Discontinuation
- 2019-05-16 AU AU2019268583A patent/AU2019268583B2/en not_active Ceased
- 2019-05-16 MX MX2020012259A patent/MX2020012259A/es unknown
- 2019-05-16 US US17/056,351 patent/US12084460B2/en active Active
- 2019-05-16 TW TW112150642A patent/TW202417000A/zh unknown
- 2019-05-16 JP JP2020564243A patent/JP7407740B2/ja active Active
- 2019-05-16 TW TW108116864A patent/TWI826446B/zh active
- 2019-05-16 CA CA3097312A patent/CA3097312A1/en active Pending
-
2020
- 2020-11-13 MX MX2023013584A patent/MX2023013584A/es unknown
- 2020-11-16 CL CL2020002967A patent/CL2020002967A1/es unknown
-
2023
- 2023-12-18 JP JP2023212606A patent/JP2024037930A/ja active Pending
-
2024
- 2024-08-06 US US18/795,371 patent/US20240391938A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3793998A1 (en) | 2021-03-24 |
| CN112119078A (zh) | 2020-12-22 |
| MX2020012259A (es) | 2021-01-29 |
| MX2023013584A (es) | 2023-11-30 |
| JP7407740B2 (ja) | 2024-01-04 |
| TWI826446B (zh) | 2023-12-21 |
| CA3097312A1 (en) | 2019-11-21 |
| KR20210013554A (ko) | 2021-02-04 |
| WO2019220390A1 (en) | 2019-11-21 |
| AU2019268583A1 (en) | 2020-10-29 |
| JP2024037930A (ja) | 2024-03-19 |
| US20210206783A1 (en) | 2021-07-08 |
| US20240391938A1 (en) | 2024-11-28 |
| TW202015698A (zh) | 2020-05-01 |
| TW202417000A (zh) | 2024-05-01 |
| US12084460B2 (en) | 2024-09-10 |
| AU2019268583B2 (en) | 2022-01-27 |
| AR117573A1 (es) | 2021-08-18 |
| BR112020022738A2 (pt) | 2021-02-02 |
| JP2021523918A (ja) | 2021-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013584A (es) | Formas cristalinas de un inhibidor de tlr7/tlr8. | |
| PE20170403A1 (es) | COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER | |
| CO2022016662A2 (es) | Derivados de triptamina deuterada y métodos de uso | |
| ZA201906209B (en) | Aryl hydrocarbon receptor antagonists and uses thereof | |
| PE20170703A1 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos | |
| ECSP19024046A (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje | |
| PH12020552148A1 (en) | Purinone compounds and their use in treating cancer | |
| CR20180307A (es) | Compuestos de imidazo[4,5-c] quinolin-2-ona y su uso en el tratamiento del cáncer | |
| PE20121276A1 (es) | Compuestos espirociclicos que contienen nitrogeno y su uso medicinal | |
| PE20191490A1 (es) | DERIVADOS DE LA PIRIMIDIN ENONA TRICICLICA PARA LA INHIBICION DE RORy Y OTROS USOS | |
| PE20152033A1 (es) | Heterociclos bicicliclos como inhibidores de fgfr | |
| GB2573668A (en) | Accelerators for composite cement compositions | |
| MX2018004954A (es) | Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer. | |
| AR047439A1 (es) | Antagonistas del receptor hidroisoindolina taquiquinina | |
| CR8842A (es) | Derivados de pirido-pirimidina, su preparacion, su aplicacion en terapeutica | |
| NZ707319A (en) | 5h-pyrrolo[3,2-d]pyrimidin-4-amine compounds and their use in the treatment of allergic diseases and other inflammatory conditions | |
| BR112017001726A2 (pt) | compostos de 6,7-di-hidropirazolo [1,5-a]pirazin-4(5h)-ona e seus usos como moduladores alostéricos negativos de receptores mglur2 | |
| PE20171104A1 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| GB2546908A (en) | Liquid anti-shrinkage agent for cement | |
| MX376971B (es) | Formulaciones de concreto ligero | |
| CL2021002667A1 (es) | Formas cristalinas de 5-bromo-2,6-di(1h -pirazol-1-il)pirimidin-4amina y nuevas sales (divisional solicitud n° 201903468). | |
| EA201991319A1 (ru) | Вакцины аттенуированного свиного гриппа и способы их изготовления и применения | |
| MX2014006824A (es) | Derivados de espirotienopiran-piperidina como antagonistas del receptor orl-1 para su uso en el tratamiento de dependencia y abuso de alcohol. | |
| EA201270143A1 (ru) | ПРИМЕНЕНИЕ БЕНЗИДАМИНА ПРИ ЛЕЧЕНИИ p40-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ | |
| CL2021000254A1 (es) | Formas cristalinas de un inhibidor de lta4h |